Morgan Stanley’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $139M | Sell |
606,348
-11,620
| -2% | -$2.6M | 0.01% | 1179 |
|
|
2025
Q4 | $132M | Buy |
617,968
+211,207
| +52% | +$43.6M | 0.01% | 1212 |
|
|
2025
Q3 | $80.9M | Buy |
406,761
+151,976
| +60% | +$28.3M | ﹤0.01% | 1598 |
|
|
2025
Q2 | $44M | Sell |
254,785
-1,648,746
| -87% | -$269M | ﹤0.01% | 2049 |
|
|
2025
Q1 | $297M | Buy |
1,903,531
+1,077,770
| +131% | +$154M | 0.02% | 666 |
|
|
2024
Q4 | $114M | Buy |
825,761
+513,273
| +164% | +$67.5M | 0.01% | 1164 |
|
|
2024
Q3 | $46.7M | Buy |
312,488
+145,519
| +87% | +$19.7M | ﹤0.01% | 1895 |
|
|
2024
Q2 | $22.8M | Buy |
166,969
+14,917
| +10% | +$2.03M | ﹤0.01% | 2507 |
|
|
2024
Q1 | $23M | Sell |
152,052
-91,700
| -38% | -$13.1M | ﹤0.01% | 2543 |
|
|
2023
Q4 | $30.7M | Buy |
243,752
+167,070
| +218% | +$16.7M | ﹤0.01% | 2945 |
|
|
2023
Q3 | $7.18M | Sell |
76,682
-7,420
| -9% | -$694K | ﹤0.01% | 3423 |
|
|
2023
Q2 | $7.51M | Sell |
84,102
-49,116
| -37% | -$4.27M | ﹤0.01% | 3443 |
|
|
2023
Q1 | $14.3M | Buy |
133,218
+50,275
| +61% | +$5.75M | ﹤0.01% | 2795 |
|
|
2022
Q4 | $10.1M | Sell |
82,943
-88,514
| -52% | -$10.3M | ﹤0.01% | 3081 |
|
|
2022
Q3 | $17.7M | Sell |
171,457
-24,890
| -13% | -$2.36M | ﹤0.01% | 2319 |
|
|
2022
Q2 | $18.3M | Buy |
196,347
+89,668
| +84% | +$8.45M | ﹤0.01% | 2395 |
|
|
2022
Q1 | $12.5M | Buy |
106,679
+43,112
| +68% | +$4.99M | ﹤0.01% | 2650 |
|
|
2021
Q4 | $8.55M | Buy |
63,567
+5,439
| +9% | +$809K | ﹤0.01% | 3116 |
|
|
2021
Q3 | $9.27M | Sell |
58,128
-20,222
| -26% | -$2.77M | ﹤0.01% | 2981 |
|
|
2021
Q2 | $10.3M | Buy |
78,350
+50,343
| +180% | +$6.71M | ﹤0.01% | 2944 |
|
|
2021
Q1 | $3.61M | Sell |
28,007
-22,653
| -45% | -$3.44M | ﹤0.01% | 3747 |
|
|
2020
Q4 | $8.45M | Buy |
50,660
+47,606
| +1,559% | +$7.87M | ﹤0.01% | 2696 |
|
|
2020
Q3 | $471K | Buy |
3,054
+200
| +7% | +$28.7K | ﹤0.01% | 4682 |
|
|
2020
Q2 | $422K | Buy |
2,854
+520
| +22% | +$71.4K | ﹤0.01% | 4688 |
|
|
2020
Q1 | $263K | Sell |
2,334
-4,508
| -66% | -$586K | ﹤0.01% | 4752 |
|
|
2019
Q4 | $952K | Buy |
6,842
+3,845
| +128% | +$427K | ﹤0.01% | 4566 |
|
|
2019
Q3 | $289K | Buy |
2,997
+1,529
| +104% | +$171K | ﹤0.01% | 4948 |
|
|
2019
Q2 | $169K | Sell |
1,468
-2,507
| -63% | -$300K | ﹤0.01% | 5091 |
|
|
2019
Q1 | $468K | Sell |
3,975
-26,588
| -87% | -$2.33M | ﹤0.01% | 4581 |
|
|
2018
Q4 | $1.92M | Sell |
30,563
-16,537
| -35% | -$1.04M | ﹤0.01% | 3807 |
|
|
2018
Q3 | $3.34M | Buy |
47,100
+16,434
| +54% | +$1.13M | ﹤0.01% | 3586 |
|
|
2018
Q2 | $2.04M | Buy |
30,666
+16,963
| +124% | +$1.12M | ﹤0.01% | 4059 |
|
|
2018
Q1 | $896K | Sell |
13,703
-49,989
| -78% | -$2.81M | ﹤0.01% | 4619 |
|
|
2017
Q4 | $2.55M | Sell |
63,692
-3,640
| -5% | -$132K | ﹤0.01% | 3812 |
|
|
2017
Q3 | $2.44M | Buy |
67,332
+26,502
| +65% | +$761K | ﹤0.01% | 3687 |
|
|
2017
Q2 | $1.13M | Buy |
40,830
+30,594
| +299% | +$808K | ﹤0.01% | 4277 |
|
|
2017
Q1 | $287K | Buy |
10,236
+9,574
| +1,446% | +$242K | ﹤0.01% | 5131 |
|
|
2016
Q4 | $13K | Buy |
+662
| New | +$13.2K | ﹤0.01% | 6097 |
|
|
2016
Q2 | – | Sell |
-25,759
| Closed | -$478K | – | 6500 |
|
|
2016
Q1 | $478K | Buy |
25,759
+22,908
| +804% | +$407K | ﹤0.01% | 4475 |
|
|
2015
Q4 | $52K | Buy |
2,851
+2,332
| +449% | +$40.9K | ﹤0.01% | 5697 |
|
|
2015
Q3 | $9K | Sell |
519
-1,141
| -69% | -$22.2K | ﹤0.01% | 6259 |
|
|
2015
Q2 | $29K | Sell |
1,660
-3,590
| -68% | -$62.8K | ﹤0.01% | 6033 |
|
|
2015
Q1 | $91K | Buy |
+5,250
| New | +$95.5K | ﹤0.01% | 5563 |
|
Other funds holding ASND
RCM
ACA
Morgan Stanley's ASND Position: Q1 2026 in Review
Morgan Stanley reduced its Ascendis Pharma A/S (ASND) stake by 1.9% in Q1 2026, selling an estimated $2.6M and leaving 606,348 shares worth $139M. The position accounts for 0.01% of the portfolio, ranked #1179.
Morgan Stanley first reported a position in ASND in Q1 2015 and has held it in 43 quarters since. The position peaked at $297M in Q1 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.
- Morgan Stanley held 606,348 shares of Ascendis Pharma A/S worth $139M as of Q1 2026.
- Morgan Stanley sold 11,620 Ascendis Pharma A/S shares in Q1 2026, an estimated $2.6M.
- Ascendis Pharma A/S made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1179 holding.
- Morgan Stanley first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 43 quarters since.
- Morgan Stanley's Ascendis Pharma A/S position peaked at $297M in Q1 2025.
- 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.